Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Pimecrolimus Cream in Atopic Dermatitis
NCT03107611Phase 3Completed
- Sponsor
- Mylan
- Start
- Feb 2016
- Primary completion
- May 2017
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 3, randomised, double-blind trial of Pimecrolimus vehicle + topical corticosteroid in atopic dermatitis (AD) (3 arms), sponsored by Mylan. Primary endpoints: Proportion of Modified Intent to Treat Subjects With Success on Investigator's Global Assessment of Disease Severity at Day 15 and Proportion of Per Protocol Subjects With Success on Investigator's Global Assessment of Disease Severity at Day 15. Started Feb 2016; status: completed.
02
Drugs
Pimecrolimus vehicle + topical corticosteroid
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT03107611.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03107611.